Form 4: ANI Pharma Exec's Tax Withholding on PSU Vesting

ANI Pharmaceuticals' SVP, Thomas Rowland, reported the withholding of 1,762 shares for tax purposes related to the vesting of performance stock units.

Summary

• Thomas Andrew Rowland, SVP, Head of Established Brands at ANI Pharmaceuticals Inc., reported a transaction on February 11, 2026.
• 1,762 shares of common stock were disposed of (withheld) for tax purposes at a price of $76.25 per share.
• This withholding is exempt under Rule 16(b)-3 and is connected to the vesting of 5,788 previously reported performance stock units.
• Following this transaction, Rowland beneficially owns 39,160 shares of ANI Pharmaceuticals Inc. common stock.
• The reported beneficial ownership also includes 128 shares acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan, which are exempt under Rule 16b-3(d) and Rule 16b-3(c).
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event, reflecting a routine executive compensation transaction (vesting and tax withholding) rather than a discretionary sale or purchase, which typically carries more significant sentiment implications.

Positives

• The vesting of performance stock units indicates that performance targets were likely met, leading to the payout.
• The transaction was executed under a Rule 10b5-1 plan, demonstrating pre-planned and compliant insider trading.

Negatives

• A portion of shares (1,762) was withheld for tax purposes, reducing the net shares received by the executive.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions like tax withholdings upon vesting are common in the pharmaceutical industry, reflecting standard executive compensation practices tied to performance and long-term incentives. This particular filing does not indicate any unusual activity compared to industry norms.

Comparison to Industry Standards

• This transaction is a standard practice for executive compensation in publicly traded companies, particularly in industries like pharmaceuticals where performance-based equity awards are prevalent.
• Companies such as Pfizer, Merck, and Johnson & Johnson frequently report similar Form 4 filings for their executives related to stock option exercises or restricted stock unit vestings where shares are withheld for tax obligations.
• The withholding of shares for taxes is a common mechanism to cover statutory tax liabilities upon the vesting of equity awards, aligning with typical compensation structures across major corporations.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event and tax withholding, not a significant open market sale. It confirms executive equity ownership and alignment with company performance.

Key Dates

Keywords

ANI Pharmaceuticals, ANIP, Form 4, Insider Transaction, Stock Vesting, Performance Stock Units, Tax Withholding, Employee Stock Purchase Plan, Rule 10b5-1